Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Hospitalized Adults 100%
• COVID-19 100%
• Remdesivir 100%
• Interferon beta-1a 100%
• Double Bind 100%
• Phase 3 Trial 100%
• Control Phase 100%
• Placebo 42%
• High-flow Oxygen 14%
• Adverse Events 9%
• Hospitalized Patients 9%
• Recovery Time 9%
• Serious Adverse Events 9%
• Every Other Day 4%
• Hazard Ratio 4%
• Loading Dose 4%
• Interferon-α (IFN-α) 4%
• Maintenance Dose 4%
• Upper Normal Limit 4%
• Disease Severity 4%
• Mechanical Ventilation 4%
• Rate Ratio 4%
• Aspartate Aminotransferase 4%
• Infectious Diseases 4%
• Symptom Severity 4%
• Breast 4%
• Alanine Aminotransferase 4%
• Room Air 4%
• Pneumonia 4%
• Japan 4%
• Impaired Renal Function 4%
• Functional Impairment 4%
• Placebo Treatment 4%
• Symptom Duration 4%
• Kaplan-Meier Estimator 4%
• Lower Respiratory Tract Infection 4%
• First Day 4%
• Mexico 4%
• One Dose 4%
• Modified Intention-to-treat 4%
• Novel Antivirals 4%
• Singapore 4%
• South Korea 4%
• Supplemental Oxygen 4%
• Group 15 Elements 4%
• Allergy Disease 4%
• SARS-CoV-2 Infection 4%
• Ordinal Scale 4%
• Remdesivir Treatment 4%
• RT-PCR Test 4%
• Peripheral Oxygen Saturation 4%
• Bad Outcomes 4%
• Related Adverse Events 4%
• Immune System Components 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Remdesivir 100%
• Beta1a Interferon 100%
• Adverse Event 22%
• Infection 4%
• Interferon 4%
• Maintenance Dose 4%
• Aspartate Aminotransferase 4%
• Antivirus Agent 4%
• Alanine Aminotransferase 4%
• Lower Respiratory Tract Infection 4%
• Disease Severity 4%
• SARS Coronavirus 4%
• Functional Disease 4%
• Diseases 4%
• Pathogenesis 4%
• Pneumonia 4%
• Disability 4%